- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
August 1st, 2009
Nanotechnology firm Liquidia Technologies has closed on just a bit more than $7 million in new financing.
According to a filing with the Securities and Exchange Commission, Liquidia raised $7,031,130 in equity funding on July 15.
Neal Fowler, the company's chief executive officer, told the Triangle Business Journal that the new funds would be used for drug design and delivery.
Its first target is a vaccine, which Liquidia hopes to have in clinical trials by late 2010, the newspaper reported.
Several pharmaceutical firms have already licensed Liquidia technology for drug development, according to Fowler.
In January, Liquidia announced a partnership with Abbott to develop means of delivering drugs through nanotechnology..
Liquidia has developed a nanotechnology program called PRINT. The process uses nanotechnology to produce thin films that can be used for light management and other uses.
|Related News Press|
News and information
Attosecond physics: Mapping electromagnetic waveforms July 25th, 2016
Accurate design of large icosahedral protein nanocages pushes bioengineering boundaries: Scientists used computational methods to build ten large, two-component, co-assembling icosahedral protein complexes the size of small virus coats July 25th, 2016
New remote-controlled microrobots for medical operations July 23rd, 2016
New probe developed for improved high resolution measurement of brain temperature: Improved accuracy could allow researchers to measure brain temperature in times of trauma when small deviations in temperature can lead to additional brain injury July 23rd, 2016